Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 739

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 739
---
 742,085 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                | ​ | ​ | ​                 | ​ | -747,933 | ​ | ​ | ​ | ​                | ​ | -684,745 | ​ | ​ |
| Accumulated other comprehensive loss                                                                                                                                                                                                                               | ​ | ​ | ​                 | ​ |      -25 | ​ | ​ | ​ | ​                | ​ |     -260 | ​ | ​ |
| Total stockholders’ equity                                                                                                                                                                                                                                         | ​ | ​ | ​                 | ​ |      707 | ​ | ​ | ​ | ​                | ​ |   57,085 | ​ | ​ |
| Total liabilities and stockholders’ equity                                                                                                                                                                                                                         | ​ | ​ | ​                 | $ |   51,329 | ​ | ​ | ​ | ​                | $ |  125,844 | ​ | ​ |

See Notes to Condensed Consolidated Financial Statements. F-2

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands, excluding share and per share data)
(unaudited)

| ​                                                                                         
 ​                                                                                         
 Revenue:                                                                                  | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months Ended 
 September 30,2024  
 ​                  | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | September 30,2023 
 ​                 | ​ |         ​ | ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months Ended 
 September 30,2024 
 ​                 | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | September 30,2023 
 ​                 | ​ |         ​ | ​ | ​ 
 ​ 
 ​ |
|:------------------------------------------------------------------------------------------|:--|:--|:-------------------|:--|----------:|:--|:--|:--|:------------------|:--|----------:|:--|:--|:--|:------------------|:--|----------:|:--|:--|:--|:------------------|:--|----------:|:--|:--|
| Collaborative revenue                                                                     | ​ | ​ | ​                  | $ |     1,298 | ​ | ​ | ​ | ​                 | $ |     2,471 | ​ | ​ | ​ | ​                 | $